Enhertu, Datroway Approvals Start Off A Big Year For Daiichi
The year is off to a good start for the Japanese pharma with back-to-back approvals in the US. CEO Ken Keller talked to Scrip about some recent setbacks and looking ahead.
The year is off to a good start for the Japanese pharma with back-to-back approvals in the US. CEO Ken Keller talked to Scrip about some recent setbacks and looking ahead.